The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource addresses the growing importance of anatomic, functional and molecular imaging in cancer research by providing Cancer Center researchers access to state-of-the-art imaging equipment, novel targeted imaging tracers, experienced technical support personnel and support for data acquisition and analysis. The CCAl shared resource includes an unparalleled array of small and large animal (clinical) imaging technologies for minimally invasive and non-destructive morphologic and physiologic imaging. The resource is comprised of two inter-related facilities within the Department of Biomedical Engineering and the School of Veterinary Medicine Teaching Hospital that house a microPET, a cyclotron and radiopharmacy, gamma camera, small animal and large animal helical CT, clinical (1.5T) and high-field (7.0T) MRI, optical (bioluminescence) imaging, ultra-high frequency and clinical ultrasound, high-resolution low-energy radiography, clinical radiography and fluoroscopy, anesthesia and monitoring equipment and animal housing for both small and large animals. The objectives of the CCAl shared resource are: 1) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving induced cancer models in small animals (primarily mice and rats) 2) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving spontaneous and induced cancer models in large animals (dog, cat, pig, etc). 3) Design and synthesize novel imaging tracers for studies involving targeted tracer delivery. 4) Provide professional consultation to investigators for design of experimental studies. 5) Provide technical support to CC members for execution of animal imaging studies and for collection and analysis of data.
The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource facilitates cancer-related research involving small and large animal imaging thereby reducing costs, increasing efficiency and improving the productivity of Cancer Center researchers through thoughtful design, execution and analysis of imaging studies.
|Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591|
|Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543|
|Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32|
|Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67|
|York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :|
|Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283|
|(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88|
|Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136|
|Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755|
|Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808|
Showing the most recent 10 out of 733 publications